Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasting and Chemotherapy in Breast Cancer
NCT07440784Completed
- Sponsor
- Khyber Medical University
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Randomised, open-label trial in breast cancer (4 arms), sponsored by Khyber Medical University. Primary endpoints: Cancer Antigen 15-3 at 4 weeks, CD4+ and CD8+ T Cell Counts at 4 weeks and 9 more. Started Aug 2022; status: completed.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07440784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07440784.